Tryptamine Compositions for Neurite Outgrowth and Neuroplasticity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for neurogenic and nootropic compositions to treat a variety of neuronal disorders and enhance cognition and sensory motor neuron functioning, as existing 5-HT-selective pharmacotherapies have limitations in addressing conditions like depression, anxiety, schizophrenia, and neurodegenerative diseases.
Innovation Solution
A composition comprising tryptamines, erinacines, hericenones, cannabinoids, and other neurogenic compounds, optionally combined with pharmaceutically acceptable excipients, to promote neurite outgrowth and enhance mental health and cognitive functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If 5-HT-selective pharmacotherapies are used to treat psychiatric disorders, then depression, anxiety, and schizophrenia can be treated, but the treatments have limitations in addressing neurodegenerative diseases and neuronal injuries
Solution Approach 1:
The patent combines multiple compound classes (tryptamines, erinacines, hericenones, cannabinoids, and other neurogenic compounds) into a single composition that targets multiple therapeutic areas including psychiatric disorders, neurodegenerative diseases, and neuronal injuries. This multi-functional approach allows one composition to address diverse conditions that previously required separate specialized treatments, thereby improving therapeutic adaptability while maintaining reliability through comprehensive coverage.
Solution Approach 2:
The invention uses a composite pharmaceutical composition integrating various bioactive compounds from different sources (mushroom extracts, plant-derived compounds, and synthetic analogs). This composite formulation synergistically combines compounds with different mechanisms of action to treat both psychiatric and neurological conditions, overcoming the limitations of single-class pharmacotherapies while ensuring reliable efficacy across multiple disease types.
2Productivity
If tryptamines are used to promote neurogenesis, then neuronal growth is enhanced, but the compositions need to be combined with multiple other compounds to achieve optimal效果
Solution Approach 1:
The patent merges tryptamines with erinacines, hericenones, cannabinoids, and other neurogenic compounds into a unified composition. This combination strategy amplifies the neurogenic effects by synergistically activating multiple pathways simultaneously (serotonin receptor activation, nerve growth factor stimulation, and neurotrophic support), thereby maximizing neurite outgrowth productivity while managing composition complexity through integrated formulation.
Solution Approach 2:
The composition is segmented into functional modules, with each compound class contributing specific neurogenic activities: tryptamines for serotonin receptor modulation, erinacines and hericenones for NGF synthesis, and cannabinoids for neuroprotective effects. This modular segmentation allows the composition to achieve comprehensive neurogenesis promotion while maintaining manageable complexity through organized functional distribution.
3Reliability
If existing pharmacotherapies are used for psychiatric disorders, then treatment is available, but they do not sufficiently address neurodegenerative diseases and cognitive impairments
Solution Approach 1:
The patent creates a universal treatment composition that effectively addresses both psychiatric disorders (depression, anxiety, schizophrenia) and neurological conditions (neurodegenerative diseases, cognitive impairments, neuronal injuries). By incorporating multiple compound classes with diverse mechanisms of action, the composition provides reliable treatment effectiveness across the entire spectrum of mental and neurological health, eliminating the need for separate specialized therapies.
Solution Approach 2:
The invention modifies the pharmacological parameters by combining compounds with different receptor affinities and mechanisms of action. This parameter change strategy enables the composition to simultaneously target serotonin receptors for psychiatric conditions and neurotrophic pathways for neurodegenerative diseases, thereby expanding disease coverage while maintaining treatment reliability through optimized pharmacological profiles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively treats serotonin receptor disorders, neuronal injuries, neurodegeneration, and cognitive impairments, enhancing neurite growth and improving mental health and cognitive functions.
Implementation Method 1
Recent studies have shown that psilocybin has neurogenerative properties. See Catlow et al., '_effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning,' Expt. Brain Res. 228: 481-491 (2013)
Implementation Method 2
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an agonist at the 5-HT2A and 5-HT2C receptors. Psilocybin's binding potency at 5-HT2A correlates with its activity as a hallucinogen in humans.
Data Source
AI summary
Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients. In another aspect, tryptamine compositions described herein enhance neuroplasticity by promoting neuronal branching through the formation of neurites (i.e., neurite outgrowth) and neurite elongation (i.e., increasing neurite length).